Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

ProQR Therapeutics N.V (PRQR) EBITDA Margin: 2021-2025

Historic EBITDA Margin for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -382.69%.

  • ProQR Therapeutics N.V's EBITDA Margin fell 16189.00% to -382.69% in Q3 2025 from the same period last year, while for Sep 2025 it was -283.87%, marking a year-over-year decrease of 14901.00%. This contributed to the annual value of -146.58% for FY2024, which is 30393.00% up from last year.
  • Per ProQR Therapeutics N.V's latest filing, its EBITDA Margin stood at -382.69% for Q3 2025, which was down 13.58% from -336.94% recorded in Q2 2025.
  • ProQR Therapeutics N.V's 5-year EBITDA Margin high stood at -41.35% for Q2 2024, and its period low was -8,668.09% during Q1 2021.
  • Moreover, its 3-year median value for EBITDA Margin was -231.25% (2025), whereas its average is -384.59%.
  • The largest annual percentage gain for ProQR Therapeutics N.V's EBITDA Margin in the last 5 years was 743,844bps (2022), contrasted with its biggest fall of 108,324bps (2022).
  • Quarterly analysis of 5 years shows ProQR Therapeutics N.V's EBITDA Margin stood at -7,565.69% in 2021, then skyrocketed by 571,847bps to -1,847.22% in 2022, then skyrocketed by 168,041bps to -166.81% in 2023, then slumped by 4,923bps to -216.04% in 2024, then tumbled by 16,189bps to -382.69% in 2025.
  • Its EBITDA Margin was -382.69% in Q3 2025, compared to -336.94% in Q2 2025 and -231.25% in Q1 2025.